Related Experiment Videos
Endothelin receptor antagonists and cerebral vasospasm: an update
Michael Chow1, Aaron S Dumont, Neal F Kassell
1Department of Neurosurgery, University of Virginia, Charlottesville, Virginia22908-0212, USA.
Neurosurgery
|November 26, 2002
Summary
Endothelin receptor antagonists show promise for treating cerebral vasospasm. This review covers recent preclinical and clinical studies, including trials for other conditions and newer drug candidates.
Area of Science:
- Neurology
- Pharmacology
Background:
- Cerebral vasospasm is a serious complication following subarachnoid hemorrhage.
- Endothelin-1 is a potent vasoconstrictor implicated in the pathophysiology of cerebral vasospasm.
Purpose of the Study:
- To review the current status of endothelin receptor antagonists (ERAs) in treating cerebral vasospasm.
- To examine recent preclinical and clinical findings, including trials for other indications and novel ERAs.
Main Methods:
- Literature review of preclinical and clinical studies.
- Analysis of clinical trials investigating ERAs.
- Examination of newer endothelin receptor antagonist agents.
Main Results:
- Endothelin receptor antagonists are being investigated for their potential to reverse or prevent cerebral vasospasm.
- Clinical trials have explored ERAs in various medical contexts, providing insights into their efficacy and safety.
- Emerging endothelin receptor antagonists demonstrate novel mechanisms and improved profiles.
Conclusions:
- Endothelin receptor antagonists represent a developing therapeutic strategy for cerebral vasospasm.
- Further research and clinical trials are warranted to establish the role of ERAs in managing this condition.